89 related articles for article (PubMed ID: 25995443)
1. MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response.
Wiemer EA; Berns EM
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995443
[No Abstract] [Full Text] [Related]
2. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
3. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
5. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
6. Recently identified drug resistance biomarkers in ovarian cancer.
Davidson B
Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
[TBL] [Abstract][Full Text] [Related]
7. Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer.
Bellati F; Gasparri ML; Caccetta J; Palaia I; Benedetti panici P
J Surg Oncol; 2012 Sep; 106(4):529; author reply 527-8. PubMed ID: 22488017
[No Abstract] [Full Text] [Related]
8. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Shu T; Li Y; Wu X; Li B; Liu Z
Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
[TBL] [Abstract][Full Text] [Related]
10. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
[TBL] [Abstract][Full Text] [Related]
11. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
12. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
13. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies.
Gachechiladze M; Škarda J; Soltermann A; Joerger M
Int J Cancer; 2017 Oct; 141(7):1286-1294. PubMed ID: 28477336
[TBL] [Abstract][Full Text] [Related]
14. [Hyperthermic intraperitoneal chemotherapy in the treatment for recurrent ovarian cancer].
Giseĭnov KD; Beliaev AM; Senchik KIu; Maksimov SIa; Urmancheeva AF; Gafton GI; Mikaia NA; Beliaeva OA; Kireeva GS; Gorodnova TV; Matveeva NS
Vopr Onkol; 2014; 60(3):343-7. PubMed ID: 25033688
[TBL] [Abstract][Full Text] [Related]
15. [Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Kajino T; Higuchi M; Hata K; Shibata N
Gan To Kagaku Ryoho; 1996 Jan; 23(1):115-7. PubMed ID: 8546461
[TBL] [Abstract][Full Text] [Related]
16. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
19. Retinoid receptor alpha and Beta expression in serous ovarian tumors.
Daponte A; Kostopoulou E; Papandreou CN; Chiotoglou I; Voutsadakis I; Vanakara P; Minas M; Nakou M; Kallitsaris A; Kollia P; Koukoulis G; Messinis IE
Oncology; 2007; 73(1-2):81-9. PubMed ID: 18334854
[TBL] [Abstract][Full Text] [Related]
20. Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
Chew I; Soslow RA; Park KJ
Int J Gynecol Pathol; 2009 Sep; 28(5):442-6. PubMed ID: 19696613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]